Novo Holdings nearly doubles earnings as Wegovy swells coffers
LONDON/COPENHAGEN (Reuters) -Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk, nearly doubled annual income and investment returns to a record 8 billion euros ($8.66 billion) in 2024, it said on Wednesday. Fuelled by dividends from the company behind blockbuster weight-loss drug Wegovy and diabetes treatment Ozempic, Novo Holdings is a life sciences investment powerhouse that manages assets for the Novo Nordisk Foundation, one of the world's biggest philanthropic bodies. "2024 was a very strong year for Novo Holdings, with our investment portfolio delivering its best ever performance," CEO Kasim Kutay said in a statement.